Master hepatitis for NEET PG 2026: hepatitis A-E virology, hepatitis B serology interpretation, HCV diagnosis and DAA therapy, hepatitis in pregnancy, drug-induced hepatitis, acute vs chronic liver failure, and vaccination schedules.
Version 1.0 — Published March 2026
Hepatitis contributes 3–5 questions per NEET PG paper. Master these 8 high-yield areas:
Hepatitis is inflammation of the liver — most commonly caused by hepatotropic viruses (A through E) but also by drugs, alcohol, autoimmune mechanisms, and metabolic conditions. In NEET PG, hepatitis B serology interpretation alone accounts for 1–2 predictable questions per paper, making it one of the highest-yield topics across medicine and microbiology. The student who masters the serology table and can read any marker combination on sight has secured reliable marks.
This guide covers every hepatitis subtype with the virology, serology, and management details that NBE tests. Pair this with MCQ practice on the Medicine subject hub and cross-reference high-yield microbiology topics for the virology classification angle.
The five hepatotropic viruses (A through E) differ in their genome, transmission route, chronicity risk, and clinical significance — and these differences are tested directly in NEET PG.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Start practicing NEET PG MCQs with AI-powered explanations.
Start Free PracticeAvoid the 10 costliest medicine mistakes in NEET PG 2026: confused anemia types, wrong hepatitis serology, diabetes diagnostic errors, thyroid function mix-ups, murmur misidentification, antibiotic selection errors, nephrotic vs nephritic confusion, acid-base disorders, ABG misinterpretation, and autoimmune marker confusion.
How AI supercharges spaced repetition for NEET PG — the neuroscience of memory, Ebbinghaus forgetting curve, adaptive scheduling, and practical implementation. Compare Anki, NEETPGAI, and manual flashcards.
An unbiased feature-by-feature comparison of NEETPGAI and Marrow for NEET PG 2026. Covers QBank, video lectures, pricing, AI features, mock tests, and which platform suits your preparation style.
Daily MCQs, study tips, and topper strategies on Telegram.
Join on Telegram →| Virus | Genome | Family | Transmission | Incubation | Chronicity | Vaccine |
|---|
| HAV | ssRNA (+) | Picornaviridae | Fecal-oral | 15–45 days | Never | Yes (inactivated) |
| HBV | dsDNA (partially) | Hepadnaviridae | Blood, sexual, vertical | 45–160 days | Yes (5% adults, 90% neonates) | Yes (recombinant) |
| HCV | ssRNA (+) | Flaviviridae | Blood (IVDU, transfusion) | 15–150 days | Yes (70–85%) | No |
| HDV | ssRNA (-), circular | Deltaviridae | Blood, sexual (requires HBV) | 30–180 days | Yes (coinfection 2%, superinfection 70%) | HBV vaccine (prevents HDV) |
| HEV | ssRNA (+) | Hepeviridae | Fecal-oral (waterborne) | 15–60 days | Rare (genotype 3 in immunocompromised) | Limited (China only) |
Key distinctions for NEET PG:
Hepatitis B serology is the pattern-based interpretation of six markers that define the stage of HBV infection — and this is arguably the single most predictable topic in NEET PG medicine and microbiology.
| Marker | What it means | When it appears |
|---|---|---|
| HBsAg | Surface antigen — virus is present | First marker to appear (1–10 weeks), persists in chronic infection |
| Anti-HBs | Surface antibody — immunity | Appears after clearance or vaccination. Protective titer: >10 mIU/mL |
| HBeAg | e antigen — active viral replication | Present during high-replication phase. Correlates with infectivity. |
| Anti-HBe | e antibody — low replication | Appears when HBeAg clears (seroconversion). Lower infectivity. |
| Anti-HBc IgM | Core IgM — acute/recent infection | Appears with symptoms, persists 4–6 months. Only marker in window period. |
| Anti-HBc IgG | Core IgG — past exposure | Appears during recovery, persists for life. Does NOT indicate immunity. |
| HBsAg | Anti-HBs | HBeAg | Anti-HBe | Anti-HBc IgM | Anti-HBc IgG | Interpretation |
|---|---|---|---|---|---|---|
| + | - | + | - | + | - | Acute hepatitis B (early) |
| + | - | + | - | + | + | Acute hepatitis B (established) |
| - | - | - | - | + | + | Window period |
| - | + | - | + | - | + | Resolved infection (natural immunity) |
| - | + | - | - | - | - | Vaccination (isolated anti-HBs) |
| + | - | + | - | - | + | Chronic HBV, HBeAg-positive (high replication) |
| + | - | - | + | - | + | Chronic HBV, HBeAg-negative (low replication or precore mutant) |
| - | - | - | - | - | - | Susceptible (needs vaccination) |
The window period is the interval between disappearance of HBsAg and appearance of anti-HBs. During this window:
Clinical significance: A patient in the window period will test negative on routine HBsAg screening but is still infected. This is why blood banks test for anti-HBc in addition to HBsAg.
HBV DNA (viral load) is measured by PCR and is the most direct indicator of viral replication:
| Drug | Class | Route | Resistance | Notes |
|---|---|---|---|---|
| Tenofovir (TDF/TAF) | Nucleotide analogue | Oral, daily | Very low | First-line (high barrier to resistance) |
| Entecavir | Nucleoside analogue | Oral, daily | Low | First-line alternative |
| Pegylated interferon alpha | Immunomodulator | SC, weekly x 48 weeks | N/A | Finite therapy, higher side effects, contraindicated in decompensated cirrhosis |
| Lamivudine | Nucleoside analogue | Oral, daily | HIGH (70% at 5 years) | Avoid as monotherapy (resistance) |
Treatment indications: HBV DNA above threshold + ALT elevated + significant fibrosis (or cirrhosis regardless of ALT).
Master NEET PG with AI-powered practice — 50,000+ MCQs with instant explanations.
Start Free Practice →Hepatitis C is a chronic viral infection caused by an RNA virus of the Flaviviridae family — notable for its high chronicity rate (70–85%) and its transformation by direct-acting antiviral (DAA) therapy from a difficult-to-treat chronic disease to a curable infection.
Epidemiology in India: Genotype 3 is the most common in India (60–70%), followed by genotype 1 (20–30%). Prevalence: 0.5–1.5% (lower than HBV but significant due to high chronicity).
Diagnosis:
Key point: Anti-HCV remains positive even after cure (unlike HBsAg which clears). Therefore, HCV RNA PCR is the test to confirm active infection and to confirm cure (SVR12).
| Regimen | Genotype coverage | Duration | SVR rate |
|---|---|---|---|
| Sofosbuvir + Velpatasvir | Pan-genotypic (1-6) | 12 weeks | >95% |
| Sofosbuvir + Ledipasvir | Genotype 1, 4, 5, 6 | 12 weeks (8 weeks if low viral load, non-cirrhotic) | >95% |
| Sofosbuvir + Daclatasvir | Pan-genotypic | 12 weeks | >90% |
| Glecaprevir + Pibrentasvir | Pan-genotypic | 8 weeks (non-cirrhotic) | >97% |
DAA drug targets:
SVR12 (Sustained Virologic Response at 12 weeks post-treatment): Undetectable HCV RNA at 12 weeks after completing therapy = CURE. Relapse after SVR12 is extremely rare (<1%).
NBE point: Interferon-based therapy (PEG-IFN + ribavirin) is OBSOLETE for HCV. DAAs have replaced it entirely. However, know that ribavirin is still teratogenic (pregnancy category X) and causes hemolytic anemia.
Hepatitis in pregnancy is a high-yield crossover topic between medicine and obstetrics — with HEV's catastrophic mortality and HBV's vertical transmission prevention being the two most tested angles.
Prevention protocol (tested repeatedly):
Breastfeeding: NOT contraindicated in HBV-positive mothers if infant has received HBIG + vaccine.
Drug-induced liver injury (DILI) is hepatotoxicity caused by medications — a critical topic tested in both pharmacology and medicine, where the examiner presents a clinical vignette of liver injury after starting a specific drug.
| Drug | Mechanism | Pattern | Key feature |
|---|---|---|---|
| Acetaminophen | Dose-dependent (NAPQI metabolite depletes glutathione) | Hepatocellular | Most common cause of ALF in the West. Antidote: N-acetylcysteine. |
| Isoniazid | Idiosyncratic (acetylator status) | Hepatocellular | Most tested drug-induced hepatitis. Monitor LFTs monthly. |
| Rifampicin | Enzyme inducer + direct hepatotoxicity | Cholestatic or mixed | Potentiates INH hepatotoxicity when combined. |
| Halothane | Immune-mediated (trifluoroacetyl metabolite) | Hepatocellular | Halothane hepatitis — massive necrosis on re-exposure. |
| Methotrexate | Cumulative, dose-dependent | Fibrosis → cirrhosis | Chronic use causes hepatic fibrosis. Monitor with liver biopsy at cumulative dose >1.5g. |
| Sodium valproate | Mitochondrial toxicity | Hepatocellular | Reye-like syndrome in children <2 years. Avoid in children under 2. |
| Amiodarone | Direct mitochondrial toxicity + phospholipidosis | Steatohepatitis → cirrhosis | Mallory-Denk bodies on biopsy (similar to alcoholic hepatitis). |
| Oral contraceptives | Estrogen-related | Cholestatic + hepatic adenoma | Benign hepatic adenoma — can rupture and hemorrhage. |
| Chlorpromazine | Immunoallergic | Cholestatic | Intrahepatic cholestasis with eosinophilia. |
R-value for classifying DILI pattern:
Acute liver failure is the rapid onset of severe hepatic dysfunction (coagulopathy + encephalopathy) in a patient WITHOUT pre-existing liver disease — developing within 26 weeks of the first sign of liver disease.
Causes in India: HEV (most common), HAV, HBV, drug-induced (acetaminophen, ATT drugs), Wilson disease (in young patients)
Classification by onset:
Management: ICU care, N-acetylcysteine (even for non-acetaminophen ALF — some evidence of benefit), monitor ICP (cerebral edema is the leading cause of death), liver transplant if King's College criteria met.
Chronic liver failure results from progressive hepatocyte loss and fibrosis over months to years — culminating in cirrhosis with portal hypertension.
Complications of cirrhosis:
Hepatitis vaccination is a preventive medicine topic tested in PSM, pediatrics, and medicine — with specific schedules and indications that NEET PG tests directly.
Hepatitis B vaccine:
Hepatitis A vaccine:
No vaccine available for: HCV (high genetic variability prevents vaccine development), HDV (prevented by HBV vaccination since HDV requires HBV co-infection)
These are the most commonly tested serology-based vignettes — practice recognizing each pattern:
Pattern 1 — "All negative except anti-HBs" → Vaccinated individual (never infected, antibody from vaccine only)
Pattern 2 — "HBsAg positive, anti-HBc IgM positive, HBeAg positive" → Acute hepatitis B with active replication
Pattern 3 — "All negative except IgM anti-HBc" → Window period (the classic trap)
Pattern 4 — "Anti-HBs positive, anti-HBe positive, anti-HBc IgG positive" → Resolved past infection with natural immunity
Pattern 5 — "HBsAg positive for 8 months, HBeAg negative, anti-HBe positive, anti-HBc IgG positive" → Chronic HBV, inactive carrier (low replication)
Pattern 6 — "Anti-HCV positive, HCV RNA detectable" → Active hepatitis C infection (needs DAA therapy)
Pattern 7 — "Anti-HCV positive, HCV RNA undetectable" → Either resolved HCV (spontaneous clearance — 15–30%) or post-treatment cure (SVR)
Hepatitis contributes 3-5 questions per NEET PG paper across medicine, microbiology, pharmacology, and obstetrics. Hepatitis B serology interpretation is the single most predictable question — it appears in nearly every paper. HCV DAA therapy and hepatitis in pregnancy are increasingly tested since 2022.
The pattern tells the story: HBsAg positive with IgM anti-HBc indicates acute infection. HBsAg positive with IgG anti-HBc and HBeAg positive indicates chronic active hepatitis B. Anti-HBs positive alone indicates vaccination. Anti-HBs positive with anti-HBc positive indicates resolved natural infection. All markers negative means susceptible — needs vaccination.
The window period is the interval between disappearance of HBsAg and appearance of anti-HBs — typically 2-16 weeks. During this period, the only positive marker is IgM anti-HBc. This is the most commonly tested serology trap in NEET PG: a patient with isolated IgM anti-HBc positivity is in the window period of acute HBV infection.
Pan-genotypic DAA (direct-acting antiviral) regimens are the first-line treatment. Sofosbuvir-velpatasvir for 12 weeks achieves SVR above 95% across all genotypes. Sofosbuvir-ledipasvir is used for genotype 1. Interferon-based therapy is obsolete. SVR12 (sustained virologic response at 12 weeks post-treatment) equals cure.
Hepatitis E virus (HEV) carries the highest mortality in pregnancy — 15-25% mortality rate in the third trimester compared to below 1% in non-pregnant individuals. HEV is waterborne (fecal-oral), endemic in India, and causes fulminant hepatic failure in pregnant women. There is no specific antiviral treatment.
Isoniazid is the most commonly tested drug cause of hepatitis in NEET PG. Other high-yield hepatotoxic drugs include acetaminophen (dose-dependent, most common cause of acute liver failure in the West), rifampicin, pyrazinamide, halothane (halothane hepatitis), methotrexate (chronic fibrosis), and sodium valproate (Reye-like syndrome in children).
The standard schedule is 0, 1, 6 months (three doses) for adults. For neonates born to HBsAg-positive mothers: HBV vaccine + HBIG (hepatitis B immunoglobulin) within 12 hours of birth, then vaccine at 1 and 6 months. Anti-HBs titer above 10 mIU/mL indicates protective immunity. Booster not routinely recommended for immunocompetent individuals.
Acute hepatitis B shows HBsAg positive with IgM anti-HBc (IgM class antibody indicates recent infection). Chronic hepatitis B shows HBsAg positive for more than 6 months with IgG anti-HBc. The persistence of HBsAg beyond 6 months defines chronicity. HBeAg status further divides chronic HBV into e-antigen positive (high replication) vs e-antigen negative.
Hepatitis serology is a pattern recognition skill — the more combinations you practice, the faster you will decode exam vignettes. Start drilling now.
See our pricing plans for unlimited access and create a personalized study plan covering the entire GI and hepatology syllabus.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: March 2026
This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.